J Korean Diabetes Assoc.  2006 Jan;30(1):47-53.

The percent change of body weight in patients with type 2 diabetes using rosiglitazone for 1 year

• Hong SB
• Park HR
• Kim EA
• Lee KW
• Nam M
• Kim YS

Abstract

BACKGROUND: Rosiglitazone(RSG) is known as a potent agonist for the PPARgamma. It improves glycemic control by improving insulin sensitivity in peripheral tissues. And it is associated with body weight gain. The Pro12Ala polymorphism of the gene encoding the peroxisome proliferator-activated receptor(PPAR)gamma2 has recently been shown to be associated with insulin sensitivity. This study was performed to evaluate the body weight change during the long term rosiglitazone treatment and the role of PPARgamma2 polymorphism, Pro12Ala as an indicator to predict the clinical response of RSG in type 2 diabetes patients. METHOD: The study subjects were 214 type 2 diabetic patients(117 male, 97 female) who were received a daily 1 year course of 4 mg RSG combined with sulfonylurea or metformin. The Pro12Ala polymorphism of the PPARgamma2 was determined by the restriction fragment length polymorphism(RFLP) method. Body weight, height, waist circumference, fasting glucose, insulin, c-peptide and lipid profile were measured.
RESULTS
After RSG treatment, body weight change was 2.4 +/- 3.8%, 4.5 +/- 9.8% of baseline body weight at 12, 24 weeks respectively. Body weight gains were increased to 5.6 +/- 10.1% at the end of 1 year. The HbA1C, serum insulin level and HOMA index were decreased following the rosiglitazone therapy. The allele frequency of the Ala12Pro polymorphism of the PPARgamma2 was 0.016. The number of Ala12Pro variant of the PPARgamma2 was too low to predict clinical response of RSG. Body weight gain was correlated with basal fasting plasma glucose, post-prandial 2 hour glucose and HbA1c level(p<0.05). There was no correlation between baseline body weight and change.
CONCLUSION
This results showed that Pro12Ala polymorphism was not acceptable for the predictor of RSG induced weight gain and clinical response. However, body weight gain was increased in who had high glucose level, and correlated positively with glucose decrease. 1st 3 month weight gain was best predictor of weight change during 1 year.

Keyword

Rosiglitazone; body weight; peroxisome proliferator-activated receptor(PPAR)gamma2

MeSH Terms

Blood Glucose
Body Weight Changes
Body Weight*
C-Peptide
Fasting
Gene Frequency
Glucose
Humans
Insulin
Insulin Resistance
Male
Metformin
Peroxisomes
PPAR gamma
Waist Circumference
Weight Gain
C-Peptide
Glucose
Insulin
Metformin
PPAR gamma

Reference

1. Spigelman BM. PPAR-γ, adipogenic regulator and thiazolidinedine receptor. Diabetes. 1998. 47:507–514.

2. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999. 22:908–912.

3. Day C. Thiazolidinediones: new class of antidiabetic drugs. Diabet Med. 1999. 16:179–192.

4. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Digail I, Morin J, Auwerx J, Ferre P. Pioglitazone induce in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 1997. 46:1393–1399.

5. Shimizu H, Tsuchyiya T, Sato N, Shimomura Y, Kobauashi I, Mori M. Troglitazone reduce plasma leptin concentration but increase hunger in NIDDM patients. Diabetes Care. 1998. 21:1470–1474.

6. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther. 2000. 22:1151–1168.

7. Stumvoll M, Hἅring H. The peroxisome proliferator-activated receptorγ2 Pro12Ala polymorphism. Diabetes. 2002. 51:2341–2347.

8. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J. The peroxisome proliferator-activated receptor γ2 Pro12Ala variant: association with type 2 diabetes and trait differences. Diabetes. 2001. 50:886–890.

9. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPAR gamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998. 20:284–287.

10. Lei HH, Chen MH, Yang WS, CHiu MC, Chen MC, Tai TY, Cjuang LM. Peroxisome prolifereator-activated receptor gamma 2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism. 2000. 49:1267–1270.

11. Kuzuya T, Kosaka K, Akanuma Y, Shigeta Y, Kaneko T. Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with NIDDM. Diabets Res Clin Pract. 1998. 41:121–129.

12. Lindi V, Sivenius K, Niskanen L, Laskos M, Uusitupa MI. Effect of the Pro12Ala polymorphism of the PPAR gamma2 gene on long-term weight change in Finnish non-diabetic subjects. Diabetologia. 2001. 44:925–926.

14. Akazawa S, Kawasaki E, Sun F, Eguchi K, Ito M. Efficacy of troglitazone on body fat distribution type 2 diabetes. Diabetes Care. 2000. 23:1067–1071.

15. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism. 2005. 54:24–32.

17. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inxucchi SE, Shulman GI, Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002. 51:797–802.

18. Altshuler D, Hirchhorn JN, Klannemark M, Lindgren CM, Vohl M-C, Nemesh J, Lane CD, Schaffner SF, Bolk A, Brewer C, Tuomi T, Vaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Gen. 2000. 26:76–80.

19. Oh EY, Min KM, Chung JH, MIn YK, Lee MS, Kim KW, Lee MK. Significance of Pro12Ala mutation in Peroxisome Proliferator-Activated Receptor γ2 in Korean diabetic and Obese Subjects. J Clin Endocrinol Metab. 2000. 85:1801–1807.

21. Stumvoll M, Wahl HS, Löblein K, Becker R, Machicao F, Jacob S, Hἅring H. Pro12Ala polymorphism in the peroxosome proliferator-activated receptor2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes. 2001. 50:876–881.

22. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso A. Two polymorphism in the peroxisome proliferator-activated receptor gene are associated with severe overweight among obese women. J Clin Endocrinol Metb. 1999. 84:3708–3712.